Sirtex Medical’s SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food...
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its latest annual Environmental, Social, and Governance (ESG) ratings. This is the first...
Coreline Soft and Temple Health to Co-Host Webinar on AI-Driven Lung Cancer Screening and Improving Patient Outcomes
Real-world outcomes: How AI improved both diagnostic efficiency, early detection, and comorbidity detection Deep dive into the precision technology of the FDA-cleared platform, AVIEW LCS Plus PHILADELPHIA and SEOUL, South Korea, July 7, 2025 /PRNewswire/ -- Coreline Soft, a leading provider of AI-based medical imaging solutions, announced it will co-host a...
The Voices of Persons Affected by Hansen’s Disease Move the World: 3rd Global Forum Held in Bali, Indonesia
TOKYO, July 7, 2025 /PRNewswire/ -- In a landmark gathering that placed lived experience at the center of global health discourse, the 3rd Global Forum of People's Organizations on Hansen's Disease was held in Bali, Indonesia, from July 4 to 6, 2025. Organized by the Sasakawa Leprosy (Hansen's Disease) Initiative, the event brought together over 110 representatives of organizations of...
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors. Dr. Thierry Abribat is a seasoned biotech executive and serial entrepreneur with a proven track record of founding, leading, and successfully...
DoH, USCF and IGI Explore Establishing the World’s first-of-their kind Centres for Genome Surgery
On the sidelines of a high-level U.S. visit ABU DHABI, UAE, July 4, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics...
Papablic Launches World’s First Portable Bottle Warmer with Built-in Sterilization
Hospital-Grade Hygiene Meets 30% Faster Heating for Parents on the Move CHICAGO, July 4, 2025 /PRNewswire/ -- Papablic, a pioneer in baby care innovation, launched the first-of-a-kind Portable Bottle Warmer with Built-in Sterilization for a simpler and safer feeding experience outside home. This Portable Bottle Warmer heats milk 30% faster than most competing products on the market with the added...
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG") areas, as well as its sustainability practices and performance in the year of 2024, systematically addressing stakeholders' concerns. Dr....
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the "2025 Everest Medicines mRNA Platform R&D Day" in Shanghai. The event unveiled significant advancements in the company's proprietary AI+mRNA platform and highlighted key cancer and autoimmune pipeline programs developed through the platform,...
Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm’s Series of Globalization Activities in Shanghai
SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the 2025 International Pharmaceutical Cooperation High-End Forum, one of the Kexing Biopharm's series of globalization activities in Shanghai. Themed on "Innovation for the World, Exploring for the Future," the event facilitated in-depth industry dialogues with...
